RxDoctor Payments DataLook up a doctor →

Anthony Martinez, MD

Internal Medicine · Buffalo, NYNPI 1598712754

Payments from drug & device makers

$1,686,530in general payments, 2019–2025

Across 1,620 payments — averaging $1041.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$807K
  • Gilead$549K
  • Madrigal Pharmaceuticals$232K
  • Cepheid$34K
  • Braeburn Inc.$17K
  • Novo Nordisk$15K
  • plus $34K from 14 others

What the payments were for

  • Consulting fees$281,04017%
  • Speaking & faculty fees$1,128,21970%
  • Travel & lodging$173,51711%
  • Food & beverage$34,6592%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,686,530 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$6,843
Medicare patients
54
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir22$550,864
XifaxanRifaximin124$396,905
BiktarvyBictegrav/Emtricit/Tenofov Ala57$229,763
RezdiffraResmetirom14$54,178
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$49,928
SuboxoneBuprenorphine Hcl/Naloxone Hcl67$48,516
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl112$23,715
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)11$16,360
Ursodiol48$9,709
Varenicline Tartrate13$4,562
ConstuloseLactulose16$3,650
Buprenorphine Hcl46$2,900
Entecavir35$2,476
Lactulose28$1,520
Tacrolimus20$1,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Biktarvy, Genvoya$548,560$830,55490 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$487$396,905124 claims
Madrigal PharmaceuticalsRezdiffra$231,612$54,17814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →